Blood Cancer Diagnostics Market: as regulators move minimal residual disease from a research endpoint toward an accepted basis for drug approval, every trial that uses MRD status to demonstrate treatment benefit now turns a monitoring test into a decision point that shapes therapy itself, so the value of an MRD assay is shifting from surveillance alone toward its role in accelerating the medicines it will eventually be used to monitor, and competitive advantage is moving toward platforms whose assays are embedded in that approval pathway.

The global blood cancer diagnostics market size was USD 11.42 Billion in 2025 and is expected to register a revenue CAGR of 7.2% during the forecast period. Market revenue growth is driven by factors such as regulatory acceptance of minimal residual disease as a clinical trial endpoint, NGS-guided precision testing protocols, and Medicare coverage expansion for MRD surveillance testing. The first driving factor is regulatory acceptance of minimal residual disease as an early endpoint for drug approval in blood cancers. The FDA's Oncologic Drugs Advisory Committee voted unanimously in April 2024 in favour of MRD negativity as a surrogate endpoint reasonably likely to predict clinical benefit in multiple myeloma trials, and the FDA released draft guidance formalising this framework in January 2026. The second driving factor is the expanding use of NGS-guided precision protocols across leukemia, lymphoma, and myeloma diagnosis and monitoring. Molecular and NGS-based tests account for approximately 52% of total 2025 market revenue, reflecting how far blood cancer diagnostics has shifted from conventional hematology toward molecular characterisation. The third driving factor is Medicare coverage expansion for MRD surveillance testing, which converts a research-oriented test into a routinely reimbursed clinical tool. These are some of the key factors driving revenue growth of the market.

A second layer of demand comes from the way a single validated MRD assay accumulates additional accepted clinical trial and reimbursement use cases over time, which converts one analytically validated test into a widening set of billable applications without a new assay platform. Once an MRD assay is accepted as a trial endpoint for one blood cancer indication, each additional accepted use, such as a new indication-specific surveillance coverage decision or a new drug-development trial design built around it, adds billable testing volume to the same underlying sequencing or flow cytometry platform, so assay value compounds as its accepted-use set widens across regulatory and reimbursement contexts. As a result, demand and revenue share are concentrating around assays with the broadest set of accepted regulatory and reimbursement uses, and the forecast tilts toward platforms embedded in both drug development and routine surveillance rather than single-purpose research tools. For instance, in April 2025, Palmetto GBA expanded Medicare coverage of Adaptive Biotechnologies' clonoSEQ assay to include six-monthly surveillance testing for up to five years during treatment-free remission in mantle cell lymphoma, extending the same NGS-based assay's reimbursed use case beyond its original diagnostic and post-treatment monitoring indications. These are some of the key factors driving revenue growth of the market.

Because MRD and comprehensive genomic profiling assays carry a meaningfully higher per-test cost than conventional hematology panels, and coverage policy varies significantly by payer and by specific blood cancer indication, community oncology practices without dedicated reimbursement specialists often default to conventional testing despite molecular testing's superior sensitivity.

Testing infrastructure concentration is a second constraint, because NGS-based and advanced flow cytometry testing requires specialised laboratory infrastructure that remains concentrated at academic cancer centres and large reference laboratories, limiting community oncology access to the most advanced diagnostic and monitoring tools.

Standardisation across laboratories is a third constraint, since MRD assay results and thresholds can vary across different sequencing platforms and laboratory protocols, which complicates cross-trial comparison and slows the pace at which any single assay can be adopted as a universal standard.

These factors substantially limit blood cancer diagnostics market growth over the forecast period.

The clearest driver of demand is regulatory acceptance of minimal residual disease negativity as an endpoint that can support accelerated drug approval in blood cancers. A surrogate endpoint works only if regulators trust that a test result predicts the long-term clinical outcome a full trial would otherwise take years to demonstrate, so FDA acceptance of MRD negativity as reasonably likely to predict progression-free and overall survival converts every MRD test administered in a supporting trial into part of the regulatory evidence package itself, not just a monitoring tool. The FDA's Oncologic Drugs Advisory Committee voted unanimously in April 2024 in favour of MRD negativity as a surrogate endpoint in multiple myeloma trials, and in January 2026 the FDA released draft guidance formally recommending how sponsors should use minimal residual disease and complete response as primary endpoints to support accelerated approval. Adaptive Biotechnologies' clonoSEQ MRD testing was featured in more than 65 abstracts at the 66th American Society of Hematology Annual Meeting in December 2024, spanning mantle cell lymphoma, chronic lymphocytic leukemia, multiple myeloma, and acute lymphoblastic leukemia. The effect on the market is that MRD assay volume is increasingly driven by pharmaceutical trial design decisions as much as by routine clinical surveillance. These are some of the key factors driving revenue growth of the market.

The second driver is the expansion of next-generation sequencing-based precision protocols as the default rather than exception in blood cancer diagnosis and monitoring. Conventional hematology panels can identify that a malignancy is present but cannot resolve the specific molecular subtype that increasingly determines treatment selection, so NGS-based testing has become necessary infrastructure wherever targeted or immunotherapy treatment decisions depend on a precise molecular diagnosis. Molecular and NGS-based tests account for approximately 52% of total 2025 market revenue, and Illumina launched its Single Cell 3' RNA Prep end-to-end workflow in January 2025, extending NGS tooling specifically into blood cancer immune profiling research applications. The effect on the market is that laboratories seeking to retain full-menu blood cancer testing contracts increasingly need NGS capability alongside conventional hematology infrastructure rather than as a separate specialty service. These are some of the key factors driving revenue growth of the market.

Adaptive Biotechnologies' clonoSEQ appeared in more than 65 abstracts at the 2024 ASH Annual Meeting across four distinct blood cancer types. A single MRD assay is now embedded across the clinical evidence base for an entire disease category.

The third driver is Medicare coverage expansion for extended-duration MRD surveillance testing beyond the initial post-treatment monitoring window. A test's commercial ceiling is set largely by how many times a payer will reimburse it per patient, so extending covered surveillance testing from a limited post-treatment window to a multi-year remission-monitoring schedule directly multiplies the billable testing events per patient without requiring any change to the underlying assay. In April 2025, Palmetto GBA, the Medicare Administrative Contractor responsible for molecular diagnostics coverage policy, expanded coverage of Adaptive Biotechnologies' clonoSEQ for mantle cell lymphoma surveillance to include six-monthly testing for up to five years during treatment-free remission. The effect on the market is that Medicare-covered MRD surveillance testing volume per patient is expanding well beyond the initial diagnostic and immediate post-treatment testing events that historically defined MRD assay revenue. These are some of the key factors driving revenue growth of the market.

However, the blood cancer diagnostics market faces severe adoption constraints from reimbursement fragmentation and the high cost of NGS-based assay panels.

Because MRD and comprehensive genomic profiling assays carry a meaningfully higher per-test cost than conventional hematology panels, and coverage policy varies significantly by payer, by Medicare Administrative Contractor jurisdiction, and by specific blood cancer indication, community oncology practices without dedicated reimbursement specialists often default to conventional testing despite molecular testing's superior sensitivity for detecting residual disease.

Testing infrastructure concentration compounds this, because NGS-based and advanced flow cytometry testing requires specialised laboratory infrastructure, bioinformatics expertise, and quality-control processes that remain concentrated at academic cancer centres and large reference laboratories, limiting community oncology access to the most advanced diagnostic and monitoring tools even where reimbursement exists.

Standardisation across laboratories is the third constraint, since MRD assay results and detection thresholds can vary across different sequencing platforms and laboratory protocols, which complicates cross-trial and cross-institution comparison and slows the pace at which any single assay can be adopted as a universal standard for a given indication.

These factors substantially limit blood cancer diagnostics market growth over the forecast period.

Based on test type, the global blood cancer diagnostics market is segmented into molecular and NGS-based tests, flow cytometry, immunohistochemistry, and conventional hematology panels. Molecular and NGS-based tests hold the largest revenue share, because MRD testing and molecular subtyping increasingly determine treatment selection across leukemia, lymphoma, and myeloma, which suits a market where regulatory acceptance of MRD as a trial endpoint has directly elevated molecular testing's clinical and commercial importance. Conventional hematology panels remain established as the first-line screening step and are cheaper per test than any molecular assay, but they cannot resolve the molecular subtype information that targeted therapy selection increasingly requires. Flow cytometry is expected to register the fastest revenue growth rate in the global blood cancer diagnostics market over the forecast period, driven by its complementary role alongside NGS-based MRD assessment in immunophenotyping, which is why reference laboratories are expanding flow cytometry capacity alongside their molecular testing infrastructure rather than treating the two as substitutes.

Multiple myeloma cancer type is expected to account for a significantly large revenue share in the global blood cancer diagnostics market during the forecast period

Based on cancer type, the global blood cancer diagnostics market is segmented into leukemia, non-Hodgkin and Hodgkin lymphoma, and multiple myeloma. Leukemia holds the largest revenue share, because its four major subtypes each require distinct molecular and cytogenetic testing protocols, which ties directly back to the NGS-guided precision testing described in the market's primary demand driver. Multiple myeloma is expected to register the fastest revenue growth rate in the global blood cancer diagnostics market over the forecast period, driven by the FDA's regulatory acceptance of MRD as a myeloma trial endpoint, which is why myeloma-focused MRD testing volume is growing fastest among all blood cancer indications as pharmaceutical sponsors build trials around the endpoint.

Based on technology, the global blood cancer diagnostics market is segmented into next-generation sequencing, PCR-based diagnostics, and FISH and cytogenetics. Next-generation sequencing holds the largest revenue share, because it is the technology underlying the MRD assays now embedded in blood cancer drug development, which ties directly back to the regulatory endpoint acceptance described in the market's primary demand driver. PCR-based diagnostics is expected to register the fastest revenue growth rate in the global blood cancer diagnostics market over the forecast period, driven by its lower cost and faster turnaround time for confirmatory testing alongside NGS-based comprehensive profiling, which is why laboratories continue to invest in both technologies rather than fully displacing PCR with sequencing.

Based on regional analysis, the blood cancer diagnostics market in North America accounted for largest revenue share in 2025. The United States leads because the concentration of FDA regulatory activity around MRD endpoints and CMS coverage determination authority creates a direct testing-to-reimbursement pathway, and because Roche, Danaher, Adaptive Biotechnologies, and Illumina all maintain their primary commercial and regulatory presence in the US market. The scale of the US academic cancer centre and NCI-designated hospital network anchors a domestic testing infrastructure large enough to sustain multiple competing molecular diagnostics platforms simultaneously. The concentration of FDA and CMS activity in the country also means new MRD coverage determinations are typically established in the United States first, before comparable frameworks develop in other regulatory jurisdictions.

The market in Europe is expected to register a steady revenue growth rate over the forecast period. Germany, the United Kingdom, and France represent the three largest national markets within Europe. Roche Diagnostics, headquartered in Switzerland, and QIAGEN, headquartered in Germany, both maintain significant European blood cancer diagnostics infrastructure. The result is steady rather than rapid growth, shaped more by national health system reimbursement negotiation and EU IVDR compliance timelines than by underlying patient demand.

The market in Asia Pacific is expected to register a rapid revenue growth rate over the forecast period. China and Japan represent the two largest national markets within the region, driven by rising blood cancer incidence and expanding NGS testing infrastructure investment. Japan is the earlier-launch market for advanced MRD testing protocols in the region, which leaves more room for growth than in the already molecular-testing-saturated North American market.

The market in Latin America is expected to register a moderate revenue growth rate over the forecast period. Brazil and Mexico represent the two largest national markets within the region, with private reference laboratory networks driving early adoption of molecular blood cancer testing among higher-income patients. The ongoing Iran-US sanctions and the resulting Strait of Hormuz shipping disruption have raised freight and import costs for the sequencing reagents and laboratory instrumentation that Latin American reference laboratories depend on, an effect expected to run through 2026 and slow blood cancer diagnostics adoption beyond Brazil's and Mexico's main urban centres.

The market in Middle East and Africa is expected to register a moderate revenue growth rate over the forecast period. Saudi Arabia and the UAE represent the primary commercial markets within the region. Saudi Arabia's expanding academic cancer centre network and the UAE's regional reference laboratory hubs represent the primary investment centres for blood cancer diagnostics adoption. Saudi Arabia is the most established market on the continent, while the Gulf states outside it are still building the molecular testing and hematopathology infrastructure needed to support MRD testing at scale.